share_log

【安信证券】仟源制药新股定位分析报告

[Anxin Securities] Qianyuan Pharmaceutical New Stock orientation Analysis report

安信證券 ·  Aug 18, 2011 00:00  · Researches

1. According to the company's prospectus, operating income in 2010 was 320 million, up 31.17% over the same period last year; net profit was 47.9836 million yuan, up 66.03% over the same period last year; according to the company's listing announcement, operating income and net profit increased by 10.7% and-8.88% from January to June 2011.

2. According to the total share capital of 133.8 million shares, the earnings per share in 2010 is 0.36 yuan. According to the unanimous expectation of the organization, the earnings per share in 2011 is estimated to be about 0.41 yuan.

3. With reference to the average PE46.89X of gem, combined with the future development prospects of the industry and the growth potential of the company's performance, give the company a dynamic valuation of 45X-55XPE in 2011.

4. According to the estimated EPS and corresponding PE levels in 2011, the current reasonable valuation should be 18.45-22.55 yuan.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment